Establishment and biological characteristics of fusions of lung cancer cell with dendritic cell

doi:10.3969/j.issn.1000-8861.2001.01.018

Abstract：Objective To explore the established method of tumor vaccinegenerated by hybrid technique and study the biological characteristics of lung cancer-dendritic fusion cell. Methods HGPRT defective Lewis lung cancer cell line， AL9901， was fused with bone marrow derived dendritic cells （DC） by PEG-1000. The phenotypes and proliferation characteristic of the fused cell were observed in vitro， and its tumor generating rate was observed in vivo.Results The DC was fused with AL9901 at a ratio of 6∶1 and the fusion rate was about 30％ and the resultant FLD-A11 hybrid cell was obtained through screening. The FLD-A11 cell could proliferate slowly in vitro and express CD80， CD40， H-2Kb， MIDC and lung cancer antigen. There was no colony formed in soft agar， and no tumor mass formed in vivo after injection of FLD-A11 at 2×106 per mice.Conclusions Lung cancer vaccine could be obtained through tumor cell fusion with DC， thereby acquired the immuno-stimulating phenotype to stimulate the specific antitumor activity in vivo. The FLD-A11 cell could be applied without danger of tumor generation. These data found a basis for the study of specific antitumor immunity and active immunotherapy of DC-based vaccine.